Pain Management at Every Step
Robexera (Robenacoxib) is the first generic to market, improving affordability for practices and clients.
Robenacoxib is the only highly COX2 selective injectable NSAID for cats and dogs and delivers precisely targeted 24-hour pain relief and anti-inflammatory support to the area of inflammation during the perioperative period1,2,3. Delivering a complete solution, the chewable yeast and meat flavoured tablets aid successful transition to at home care.
The range also provides the following benefits:
- Best safety profile NSAID for cats1
- Controls acute and chronic pain in cats and OA in dogs4
- Rapid elimination from bloodstream lowers broader systemic exposure5
Robexera is bioequivalent to the originator product 6,7
Comparison of mean plasma profiles of robenacoxib
Comparison of mean plasma profiles (Log-Linear) of robenacoxib for dogs after administration of the test product robenacoxib Krka Robexera 20 mg tablets and the reference product tablets 20 mg.
1. Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal ofVeterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052. 2. Kongara K. , Chambers J.C. (2018) “Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy and place in therapy.” Veterinary medicine (Auckland, N.Z.) vol. 9 53-61. 15 Aug.2018, doi:10.2147/VMRR.S170893. 3. Silber HE, et al. Pharm Res 2010;27:2633–2645. 4. Robexera® SPC. Available at: https://www.vmd.defra.gov.uk/ProductInformationDatabase. 5. Toutain CE, et al. BMC Vet Res 2018;14:242. 6. https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/UKPAR_Documents/UKPAR_3021536.PDF. 7. Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure UK(GB) Vm 01656/5117; PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; available on https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/UKPAR_Documents/UKPAR_2665658.PDF
Robexera for Cats – Injection and Tablets
The best proven safety profile for cats of any NSAID1
Robexera (Robenacoxib), provides a simple, cost-effective pain management solution and is available in versatile injection and tablets formats that are fully interchangeable2 through the treatment plan.
The range also provides the following benefits:
- Controls acute and long-term chronic pain, including OA3
- Reduces pain and inflammation to optimise post-surgical recovery3
- Highly COX2 selective, targeting the site of inflammation for up to 24 hours1,4,5
- Rapid elimination from bloodstream lowers broader systemic exposure6
Other benefits of Robexera tablet and injection for cats include
Robexera Chewable tablet has been
formulated to aid administration
The Robexera tablet contains two
palatability components – yeast and
hydrolyzed vegetable protein (meat flavour)
as part of its chewable formulation.
Along with this, the small 6mm tablet
compares to a typical dry cat food kibble
diameter of ~6–10 mm to aid administration.
Robexera (robenacoxib) differentiates from other NSAIDs
The only coxib
registered for
cats8
Designed to
concentrate
at the
inflammation
site1
24hrs efficacy
in the
area with
inflammatory
exudates1,4
Fast onset:
COX-2
inhibition
within the
first hour3
Built for longerterm
use.
No accumulation
with a wide
safety margin1,11
Comparison of Robenacoxib and Meloxicam NSAID injection and tablets
Combined with Krka’s commitment to product efficacy, Robexera enables wider NSAID choice for the surgical care of cats.
More information
- Robexera for Cats detailer
- Find out about Robexera Injection and Tablets for Dog
- Contact your Krka Account Manager for more information – KRKA UK ANIMAL HEALTH TEAM | Krka
1. Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052. 2. Heit MC, Stallons LJ, Seewald W, Thompson CM, Toutain CE, King SB, Helbig R. Safety evaluation of theinterchangeable use of robenacoxib in commercially-available tablets and solution for injection in cats. BMC Veterinary Research. 2020;16:355. doi:10.1186/s12917-020-02553-7 3. Robexera® SPC. Available at:https://www.vmd.defra.gov.uk/ProductInformationDatabase. 4. Kongara K. , Chambers J.C. (2018) “Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy and place in therapy.” Veterinary medicine (Auckland, N.Z.) vol. 9 53-61. 15 Aug.2018, doi:10.2147/VMRR.S170893. 5. Silber HE, et al. Pharm Res 2010;27:2633–2645. 6. Toutain CE, et al. BMC Vet Res 2018;14:242. 7. Regulatory approved biowaiver demonstrating bioequivalence to the reference (Registration procedure UK(GB)Vm 01656/5117; PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; available on https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/UKPAR_Documents/UKPAR_3147525.PDF. 8. Kamata et al. (2012) Comparison of injectable Robenacoxib versus meloxicam for peri-operative use in cats:results of a randomised clinical trial. The Veterinary Journal vol. 193, Issue 1, July 2012, Pages 114-115. 9. Rosa l. et al (2024) Effects of Robenacoxib on the minimum alveolar concentration of isoflurane in domestic felines. Arquivo Brasileiro de Medicina Veterinária e Zootecnia 76(6) DOI:10.1590/1678-4162-13111. 10. https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/UKPAR_Documents/UKPAR_3021536.PDF. 11. King JN, Jung M, Maurer MP, Schmid VB, Seewald W, Lees P. Effects of route of administration and feeding schedule on pharmacokinetics of robenacoxib in cats. Am J Vet Res. 2013 Mar;74(3):465-72. doi: 10.2460/ajvr.74.3.465.PMID: 23438125. 12. Metacam:https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documents/SPC_2177183.PDF.
Robexera for Dogs – Injection and Tablets
Robexera (Robenacoxib) provides a simple, cost-effective pain management solution, and is available in versatile injection and tablets formats that are fully interchangeable1 through the treatment plan. The dog range comes in 4 strengths with colour-coded boxes, fully perforated blisters and a set of PIL sheets per pack that covert to prescribing envelopes.
The range also provides the following benefits:
- Controls pain and inflammation associated with chronic OA and soft tissue surgery3
- Highly COX2 selective, targeting the site of inflammation for up to 24 hours2,3,4
- Rapid elimination from bloodstream lowers broader systemic exposure5
Other benefits of Robexera tablet and injection for dogs include
Robexera (robenacoxib) differentiates from other NSAIDs
Designed to
concentrate
at the
inflammation
site2
24hrs efficacy
in the area with
inflammatory
exudates9
Fast onset: COX-2
inhibition within the
first hour8
Built for longer-term
use. Provides a fast
onset of action and rapid
elimination of excess
from the blood.1
Fast onset of action, low volume of distribution and rapid elimination of excess from blood and well perfused organs2 reduce wider systemic impact
More information
- Robexera for Dogs detailer
- Find out about Robexera Injection and Tablets for Cats
- Contact your Krka Account Manager for more information – KRKA UK ANIMAL HEALTH TEAM | Krka
1. Robexera SPC Robexera 20 mg/ml solution for injection for cats and dogs – https://www.vmd.defra.gov.uk/. 2. Lees, P., et al. (2022). Pharmacology, safety, efficacy and clinical uses of the COX-2 inhibitor robenacoxib. Journal of Veterinary Pharmacology and Therapeutics, 45, 325–351. https://doi.org/10.1111/jvp.13052. 3. Robexera® SPC. Available at: https://www.vmd.defra.gov.uk/ProductInformationDatabase. 4. Silber HE, et al.(2010) Population pharmacokinetic analysis of blood and joint synovial fluid concentrations of robenacoxib from healthy dogs and dogs with osteoarthritis. Pharm Res 27:2633-2645. doi: 10.1007/s11095-010-0262z. 5. Toutain, C.E., Brossard, P., King, S.B. et al. Six-month safety evaluation of robenacoxib tablets (Onsior™) in dogs after daily oral administrations. BMC Vet Res 14, 242 (2018).https://doi.org/10.1186/s12917-018-1566-1. 6. Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure UK(GB)Vm 01656/5117; PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; available on https://www.vmd.defra.gov.uk/productinformationdatabase/files/UKPAR_Documents/UKPAR_3147525.PDF. 7. Robexera SPC Robexera 20 mg/ml solution for injection for cats and dogs – https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documents/SPC_3090863.PDF. 8. Robexera SPC Robexera 40 mg chewable tablets for dogs – https://www.vmd.defra.gov.uk/productinformationdatabase/files/SPC_Documents/SPC_2610463.PDF. 9. Kongara K. , Chambers J.C. (2018) “Robenacoxib in the treatment of pain in cats and dogs: safety, efficacy and place in therapy.” Veterinary medicine (Auckland, N.Z.) vol. 9 53-61. 15 Aug.2018, doi:10.2147/VMRR.S170893. 10. Metacam SPC 5 mg/ml solution for injection for dogs and cats – https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documents/SPC_2177032.PDF. 11. Firocoxib: https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documents/SPC_2280474.PDF. 12. Cimicoxib: https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documen s/SPC_2740815.PDF. 13. Metacam SPC 2.5 mg chewable tablets for dogs – https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/SPC_Documents/SPC_2177183.PDF 14. Regulatory approved Biowaiver demonstrating bioequivalence to the reference (Registration procedure UK(GB)
Vm 01656/5117; PUBLICLY AVAILABLE ASSESSMENT REPORT FOR A VETERINARY MEDICINAL PRODUCT; available on –
https://www.vmd.defra.gov.uk/ProductInformationDatabase/files/UKPAR_Documents/UKPAR_2665658.PDF
Robexera contains Robenacoxib (POM-V). Further information available in the SPC or from Krka UK Ltd, Thames House, Waterside Drive, Langley, SL3 6EZ, United Kingdom. Tel: 020 7164 6156. Email: animalhealth.uk@krka.biz | www.krka.co.uk Copyright © Krka UK Ltd 2026 | ® Registered trademarks of Krka d.d. Novo Mesto | Krka UK. Date of preparation: July 2026.
USE MEDICINES RESPONSIBLY | Prescription decisions are for the person issuing the prescription alone.